409 Illinois Street
San Francisco, CA 94158
FibroGen, Inc. discovers, develops, and commercializes drugs for anemia and pulmonary fibrosis. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was founded in 1993 and is headquartered in San Francisco, California.